泰奥菲林在预防血管综合征复发中的作用
Bratislavske lekarske listy
|November 2, 2024
概括
口服西奥菲林显著减少了对其他治疗无反应的患者的血管综合征复发. 然而,大约三分之一的患者因胃肠不耐受等副作用而停止服用西奥菲林.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血中腺水平升高与引发血管综合症有关.
- 西奥菲林作为腺受体对抗剂,表明潜在的治疗作用.
研究的目的:
- 评估口服西奥菲林在预防复发性血管综合症方面的疗效和患者服药性.
- 在非药理学措施失败时评估theophylline的有效性.
主要方法:
- 一项研究涉及44名患者 (8名男性,34名女性) 诊断出血管.
- 在非药物治疗被证明无效后,患者接受了口服神林治疗,剂量根据需要进行调整.
- 随访评估每6个月进行一次,平均时间为17.1个月.
主要成果:
- 综合性发作总数显著下降,从每名患者的平均4.8个减少到1.73个 (p=0.0006).
- 综合性发作每年的发生率从每年4.07降至1.50 (p=0.001).
- 34名患者没有出现同性复发,而10名患者继续出现发作;14名患者因副作用 (胃肠不耐受,心,头痛) 暂停治疗.
结论:
- 口服西奥菲林,当添加到非药物策略时,显著减少了血管综合征的复发.
- 尽管它是有效的,但很大一部分患者 (约三分之一) 由于副作用而停止服用西奥菲林.
更多相关视频
05:39Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
1.4K
04:48Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
Published on: November 28, 2018
7.9K
相关概念视频
Antiasthma Drugs: Methylxanthines
198
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
198
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
709
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
709
Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
Heart Failure Drugs: Inotropic Agents
525
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
782
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
782
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
914
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
914
